Publication details

Bezpečnost léčby dabigatran etexilátem

Title in English Safety of therapy with dabigatran etexilate
Authors

PENKA Miroslav MICHALCOVÁ Jana BULIKOVÁ Alena ZAVŘELOVÁ Jiřina

Year of publication 2016
Type Article in Proceedings
Conference XVIII. Brněnský geriatrický den
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords dabigatran; bleeding; idarucizumab; antidote
Description Bleeding still represents the most feared complication of anticoagulant therapy, despite its lower incidence in patients on new antithrombotics. The management of bleeding mostly consists of nonspecific therapeutic measures, in case of dabigatran there is a specific antidote available (idarucizumab).

You are running an old browser version. We recommend updating your browser to its latest version.

More info